Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$109.86 USD

109.86
108,587

-0.71 (-0.64%)

Updated May 14, 2024 04:00 PM ET

After-Market: $109.67 -0.19 (-0.17%) 4:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

New Strong Buy Stocks for May 23rd

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

    Use Rising P/E Tactic to Find Out 5 Winning Stocks

    by Zacks Equity Research

    Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.

      Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

      by Zacks Equity Research

      Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.

        HealthSouth Corp (HLS) Looks Good: Stock Moves 8% Higher

        by Zacks Equity Research

        HealthSouth Corporation (HLS) shares rose almost 8% in the last trading session.

          Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y

          by Zacks Equity Research

          Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.

            Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion

            by Zacks Equity Research

            Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.

              VIVUS to Regain Commercial Rights for Stendra from Sanofi

              by Zacks Equity Research

              VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.

                Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

                by Zacks Equity Research

                Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

                  Allergan's Restasis Now Available in Multidose Bottle in U.S.

                  by Zacks Equity Research

                  Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.

                    Alexion (ALXN) Files for Soliris' Label Expansion in Japan

                    by Zacks Equity Research

                    Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).

                      Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study

                      by Zacks Equity Research

                      Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.

                        Keryx's Auryxia Added to Largest Medicare Part D Plan

                        by Zacks Equity Research

                        Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.

                          Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down

                          by Zacks Equity Research

                          Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.

                            Jazz Sleep Disorder Drug Positive in Phase III Studies

                            by Zacks Equity Research

                            Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.

                              BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet

                              by Zacks Equity Research

                              BioDelivery Sciences International, Inc. (BDSI) reported loss of 29 cents per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of 28 cents.

                                Owens & Minor (OMI) Reaffirms Tepid 2017 Financial Guidance

                                by Zacks Equity Research

                                Owens & Minor Inc. (OMI) outlined its new strategic plan and reaffirmed the financial guidance.

                                  Teva Launches Authorized Generic of Allergan's Minastrin

                                  by Zacks Equity Research

                                  Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.

                                    Jazz Initiates Phase III Study for Narcolepsy Candidate

                                    by Zacks Equity Research

                                    Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.

                                      Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4

                                      by Zacks Equity Research

                                      Conatus Pharmaceuticals Inc. (CNAT) reported fourth-quarter 2016 loss of 35 cents per share, wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago figure of 30 cents.

                                        TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4

                                        by Zacks Equity Research

                                        TrovaGene Inc. (TROV) reported loss of 31 cents per share in the fourth quarter of 2016, 2 cents wider than the Zacks Consensus Estimate.

                                          Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4

                                          by Zacks Equity Research

                                          Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.

                                            AstraZeneca's Cancer Drug Lynparza Positive in Phase III

                                            by Zacks Equity Research

                                            AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.

                                              Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up

                                              by Zacks Equity Research

                                              Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents.

                                                Cogentix (CGNT) Q4 Earnings and Revenues Miss Estimates

                                                by Zacks Equity Research

                                                Cogentix Medical, Inc. (CGNT) reported adjusted loss of 14 cents per share in the fourth quarter of 2016.

                                                  Luminex Projects Strong Q4 Revenues, Issues 2017 Guidance

                                                  by Zacks Equity Research

                                                  Luminex Corporation (LMNX) announced that it expects revenues in the fourth quarter of 2016 to be approximately $72 million and approximately $271 million for full-year 2016.